Topic: Clostridium difficile
Pfizer's Staphylococcus aureus vaccine candidate was among a group of pipeline shots the company hoped could propel growth beyond Prevnar 13.
Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
By the numbers, Sanofi’s vaccines business did quite well in 2017. Revenue grew an impressive 8.3% to reach €5.1 billion ($6.12 billion). But beyond the income statement, last year wasn’t without headline-hogging controversies and setbacks.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.